NASDAQ: PASG
Passage Bio Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their PASG stock forecasts and price targets.

Forecast return on equity

Is PASG forecast to generate an efficient return?

Company
-773.03%
Industry
29.99%
Market
177.22%
PASG's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PASG forecast to generate an efficient return on assets?

Company
-136.83%
Industry
20.46%
PASG is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PASG earnings per share forecast

What is PASG's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$9.98
Avg 2 year Forecast
-$10.40
Avg 3 year Forecast
-$9.05

PASG revenue forecast

What is PASG's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

PASG vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PASG$3.46N/AN/A
CLRB$1.15$10.00+769.57%Strong Buy
HIND$1.63$3.50+114.72%Strong Buy
KAPA$0.46N/AN/A
TVRD$0.87$9.20+963.58%Strong Buy

Passage Bio Stock Forecast FAQ

What is PASG's earnings growth forecast for 2026-2028?

(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32%.

Passage Bio's earnings in 2026 is -$36,112,000.On average, 5 Wall Street analysts forecast PASG's earnings for 2026 to be -$32,099,585, with the lowest PASG earnings forecast at -$30,840,778, and the highest PASG earnings forecast at -$33,043,691. On average, 4 Wall Street analysts forecast PASG's earnings for 2027 to be -$33,478,095, with the lowest PASG earnings forecast at -$32,165,229, and the highest PASG earnings forecast at -$34,462,745.

In 2028, PASG is forecast to generate -$29,112,814 in earnings, with the lowest earnings forecast at -$27,971,135 and the highest earnings forecast at -$29,969,073.

If you're new to stock investing, here's how to buy Passage Bio stock.

What is PASG's revenue growth forecast for 2026-2028?

(NASDAQ: PASG) Passage Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.99%.

Passage Bio's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast PASG's revenue for 2026 to be $0, with the lowest PASG revenue forecast at $0, and the highest PASG revenue forecast at $0. On average, 4 Wall Street analysts forecast PASG's revenue for 2027 to be $0, with the lowest PASG revenue forecast at $0, and the highest PASG revenue forecast at $0.

In 2028, PASG is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is PASG's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PASG) forecast ROA is -136.83%, which is lower than the forecast US Biotechnology industry average of 20.46%.

What is PASG's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PASG) Passage Bio's current Earnings Per Share (EPS) is -$11.33. On average, analysts forecast that PASG's EPS will be -$9.98 for 2026, with the lowest EPS forecast at -$9.58, and the highest EPS forecast at -$10.27. On average, analysts forecast that PASG's EPS will be -$10.40 for 2027, with the lowest EPS forecast at -$10.00, and the highest EPS forecast at -$10.71. In 2028, PASG's EPS is forecast to hit -$9.05 (min: -$8.69, max: -$9.31).

What is PASG's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PASG) forecast ROE is -773.03%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.